Drug · DIN 02240352
INTEGRILIN
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since October 17, 2022; first marketed June 23, 1999.
- Drug Identification Number (DIN)
- 02240352
- Company (DIN owner)
- Merck Canada IncKirkland, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Eptifibatide B01AC16
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| EPTIFIBATIDE | 2 MG | ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- March 7, 2011: NOC 12132New Drug Submission (NDS) · Manufacturer name change
- September 26, 2005: NOC 7435New Drug Submission (NDS) · Manufacturer name change
- April 3, 2002: NOC 491New Drug Submission (NDS) · Manufacturer name change
- June 11, 1999: NOC 1764New Drug Submission (NDS)
Other DINs named INTEGRILIN
- DIN 02240351 · Cancelled Post Market